Technical Analysis for THAR - Tharimmune, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Crossed Above 20 DMA | Bullish | 2.88% | |
Crossed Above 50 DMA | Bullish | 2.88% | |
Pocket Pivot | Bullish Swing Setup | 2.88% | |
Wide Bands | Range Expansion | 2.88% | |
Oversold Stochastic | Weakness | 2.88% |
Alert | Time |
---|---|
20 DMA Support | about 22 hours ago |
50 DMA Support | about 22 hours ago |
Down 3% | about 22 hours ago |
Down 2 % | about 22 hours ago |
Down 1% | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 71.8485 |
52 Week Low | 1.835 |
Average Volume | 1,516,320 |
200-Day Moving Average | 4.08 |
50-Day Moving Average | 2.42 |
20-Day Moving Average | 2.43 |
10-Day Moving Average | 2.31 |
Average True Range | 0.40 |
RSI (14) | 52.83 |
ADX | 29.65 |
+DI | 31.73 |
-DI | 21.74 |
Chandelier Exit (Long, 3 ATRs) | 5.19 |
Chandelier Exit (Short, 3 ATRs) | 3.05 |
Upper Bollinger Bands | 3.18 |
Lower Bollinger Band | 1.68 |
Percent B (%b) | 0.55 |
BandWidth | 61.98 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0017 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.93 | ||||
Resistance 3 (R3) | 2.92 | 2.75 | 2.86 | ||
Resistance 2 (R2) | 2.75 | 2.64 | 2.76 | 2.84 | |
Resistance 1 (R1) | 2.63 | 2.57 | 2.69 | 2.64 | 2.81 |
Pivot Point | 2.46 | 2.46 | 2.50 | 2.47 | 2.46 |
Support 1 (S1) | 2.34 | 2.35 | 2.40 | 2.36 | 2.19 |
Support 2 (S2) | 2.17 | 2.28 | 2.18 | 2.16 | |
Support 3 (S3) | 2.05 | 2.17 | 2.14 | ||
Support 4 (S4) | 2.07 |